Priyanka Sharma, MD

Professional Background

Dr. Priyanka Sharma is a Professor of Medicine at the University of Kansas Medical Center and assistant director of clinical research and co-program leader for the Drug Discovery, Delivery andamp; Experimental Therapeutics program at the University of Kansas Cancer Center. She is the institutional principal investigator for South West Oncology Group (SWOG) and co-PI for MCA-KUCC NCORP grant.

Dr. Sharma received her medical degree from MS University of Baroda, India and proceeded to complete Internal Medicine residency, chief residency, and Hematology-Oncology fellowship at the University of Kansas Medical Center. Her research interests include clinical and translational research in triple-negative breast cancer (TNBC) and novel treatment strategies for metastatic breast cancer.

Dr. Sharma is recipient of several grants including American Society of Clinical Oncology (ASCO) Advanced Clinical Research Award, Mary-Kay Foundation grant and is principle investigator of several ongoing clinical trials with targeted agents.

Dr. Sharma is Vice-Chair of the South West Oncology Group (SWOG) Breast Committee, member of SWOG Board of Governors and member of NCI breast cancer steering committee.

• MBBS, University of Baroda, Baroda, Gujurat
• Internship, Rural Health Service and Obstetrics/Gynecology, Baroda Medical College, Baroda , Gujurat
• Internship, Community Health Service and Internal Medicine, Baroda Medical College, Baroda, Gujurat
• Residency, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Residency, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Clinical Fellowship, Division of Hematology/Oncology, University of Kansas School of Medicine, Kansas City, KS

• American Board of Internal Medicine - Medical Oncology
• Kansas

• Southwest Oncology Group, SWOG Breast Committee, Vice Chair, 2018 - Present
• American Society of Clinical Oncology, American Society of Clinical Oncology, Member, 2001 - Present

---

Research

Overview

I am a Professor of Medicine in the Department of Internal Medicine, Division of Oncology, as well as the Assistant Director for Clinical Research within the University of Kansas Cancer Center (KUCC). I am the Vice-Chair of the SWOG Breast Committee and have been member of the SWOG Board of Governors since 2015. I am a member of the American Society of Clinical Oncology (ASCO) scientific program committee, for which I also serve as breast cancer track leader for 2018-2019. In addition to national and institutional leadership roles, I am very actively involved in clinical and translational breast cancer research. My long-term research goal is to delineate personalized treatment strategies for triple-negative breast cancer (TNBC) and BRCA mutation-associated breast cancer. I serve as Translational PI of an ongoing CTEP-funded SWOG trial for patients with TNBC (S1416) and as PI of an active translational SWOG study (S9313c) which also focuses on TNBC. Outside of SWOG I have served as PI of several neoadjuvant therapeutic investigator-initiated trials for TNBC.

• Phase II trial of Neoadjuvant Carboplatin, Docetaxel plus Pembrolizumab in Stage I-III Triple-Negative Breast Cancer (NeoPACT), Merck & Co, Inc., PI
• The University of Kansas Cancer Center - Midwest Cancer Alliance Rural NCORP (KUCC-MCA Rural NCORP), NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites UG1, Co-PI

• Sharma, P, Abramson, V., G, O'Dea, A., P, Nye, L, Mayer, I., A, Pathak, H., B, Hoffmann, M, Stecklein, S., R, Elia, M, Lewis, S, Scott, J, De Jong, J., A, Wang, Y., Y, Yoder, R, Schwensen, K, Finke, K, Heldstab, J, LaFaver, S, Williamson, S, Phadnis, M., A, Reed, G., A, Kimler, B., F, Khan, Q., J, Godwin, A., K. 2021. Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research
• Sharma, P. 2020. Major strides in HER2 blockade for metastatic breast cancer [editorial]. N Engl J Med
• Sharma, P, Barlow, W., E, Godwin, A., K, Parkes, E., E, Knight, L., A, Walker, S., M, Kennedy, R., D, Harkin, D., P, Logan, G., E, Steele, C., J, Lambe, S., M, Badve, S, Gökmen-Polar, Y, Pathak, H., B, Isakova, K, Linden, H., M, Porter, P, Pusztai, L, Thompson, A., M, Tripathy, D, Hortobagyi, G., N, Hayes, D., F. 2019. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 (36), 3484-3492
• Sharma, P, Barlow, WE, Godwin, AK, Pathak, H., Isakova, K, Williams, D., Timms, KM, Hartman, A.., R., Wenstrup, R.., J., Linden, HM, Tripathy, D, Hortobagyi, G.N, Hayes, DF. 2018. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol, 29 (3), 654-660. https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdx821/4774220?searchresult=1
• Sharma, P., Lopez-Tarruella, S., Garcia-Saenz, J.., A., Khan, Q.., J., Gomez, H., Prat, A., Moreno, F., Jerez-Gilarranz, Y., Barnadas, A., Picornell, A.., C., Del Monte-Millan, M., Gonzalez-Rivera, M., Massarrah, T., Pelaez-Lorenzo, B., Palomero, M.., I., Gonzalez Del Val, R., Cortes, J., Fuentes Rivera, H., Bretel Morales, D., Marquez-Rodas, I., Perou, C.., M., Lehn, C., Wang, Y.., Y., Klemp, J.., R., Mammen, J.., M., Wagner, J., Amin, A., O'Dea, A.., P., Heldstab, J., Jensen, R.., A., Kimler, B.., F., Godwin, A.., K., Martin, M.. 2018. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res, 24 (23), 5820-5829. https://www.ncbi.nlm.nih.gov/pubmed/30061361 | http://clincancerres.aacrjournals.org/content/clincanres/early/2018/07/28/1078-0432.CCR-18-0585.full.pdf
• Sharma, P., Lopez-Tarruella, S., Garcia-Saenz, J.., A., Ward, C., Connor, C.S., Gomez, H.., L., Prat, A., Moreno, F., Jerez-Gilarranz, Y., Barnadas, A., Picornell, A., Del Monte-Millan, M., Gonzalez-Rivera, M., Massarrah, T., Pelaez-Lorenzo, B., Palomero, M.., I., Gonzalez Del Val, R., Cortes, J., Fuentes Rivera, H., Bretel Morales, D., Marquez-Rodas, I., Perou, C.., M., Wagner, J., Mammen, J.., M., McGinness, M., Klemp, J.., R., Amin, A., Fabian, C.., J., Heldstab, J., Godwin, A.., K., Jensen, R.., A., Kimler, B.., F., Khan, Q.., J., Martin, M.. 2017. Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: combined analysis of two cohorts. Clin Cancer Res, 23 (3), 649-657. http://clincancerres.aacrjournals.org/content/clincanres/23/3/649.full.pdf
• Bhatti, S, Heldstab, J., Lehn, C., Tawfik, O., Ash, RM, Hout, D.., R., Seitz, R.., S., Bailey, D.., B., O'Dea, A.P, Jensen, R.., A., Khan, QJ, Godwin, A.., K., Sharma, P. 2017. Clinical activity of pembrolizumab in a patient with metastatic triple-negative breast cancer without tumor programmed death-ligand 1 expression: a case report and correlative biomarker analysis. JCO Precis Oncol (1), 1-6. http://ascopubs.org/doi/pdf/10.1200/PO.17.00032
• Prochaska, L.., H., Sharma, P. 2016. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer [editorial]. Breast Diseases: a YB Quarterly, 27 (3), 218-220
• Couch, F.., J., Hart, S.., N., Sharma, P., Toland, A.., E., Wang, X., Miron, P., Olson, J.., E., Godwin, A.., K., Pankratz, V.., S., Olswold, C., Slettedahl, S., Hallberg, E., Guidugli, L., Davila, J.., I., Beckmann, M.., W., Janni, W., Rack, B., Ekici, A.., B., Slamon, D.., J., Konstantopoulou, I., Fostira, F., Vratimos, A., Fountzilas, G., Pelttari, L.., M., Tapper, W.., J., Durcan, L., Cross, S.., S., Pilarski, R., Shapiro, C.., L., Klemp, J., Yao, S., Garber, J., Cox, A., Brauch, H., Ambrosone, C., Nevanlinna, H., Yannoukakos, D., Slager, S.., L., Vachon, C.., M., Eccles, D.., M., Fasching, P.., A.. 2015. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol, 33 (4), 304-11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302212/pdf/zlj304.pdf